Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 5.25 (-4.55%)
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which...

TSHA : 5.25 (-4.55%)
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based...

TSHA : 5.25 (-4.55%)
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic...

TSHA : 5.25 (-4.55%)
Citizens JMP Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)

In a report released today, Silvan Tuerkcan from Citizens JMP reiterated a Buy rating on Taysha Gene Therapies, with a price target of $6.00. The company’s shares closed last Friday at $4.88.Elevate...

TSHA : 5.25 (-4.55%)
Truist Financial Remains a Buy on Taysha Gene Therapies (TSHA)

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Taysha Gene Therapies. The company’s shares closed yesterday at $5.00.Elevate Your Investing Strategy: Take advantage...

TSHA : 5.25 (-4.55%)
Canaccord Genuity Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies, with a price target of $14.00. The company’s shares closed yesterday at $5.00.Elevate...

TSHA : 5.25 (-4.55%)
Taysha Gene Therapies Presents Promising TSHA-102 Data

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Taysha Gene...

TSHA : 5.25 (-4.55%)
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced...

TSHA : 5.25 (-4.55%)
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Masimo (MASI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Taysha Gene Therapies (TSHA – Research Report) and Masimo (MASI – Research Report) with bullish sentiments.Elevate...

MASI : 127.40 (-2.05%)
TSHA : 5.25 (-4.55%)

Barchart Exclusives

3 Best Dividend Aristocrats to Buy in 2026
These Dividend Aristocrats have strong earnings growth, solid yields, and Wall Street buy ratings stand out as smart income plays for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar